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Abstract
Background: The human malaria parasite remains a burden in developing nations. It is responsible for up to one
million deaths a year, a number that could rise due to increasing multi-drug resistance to all antimalarial drugs
currently available. Therefore, there is an urgent need for the discovery of new drug therapies. Recently, our
laboratory developed a simple one-step fluorescence-based live cell-imaging assay to integrate the complex
biology of the human malaria parasite into drug discovery. Here we used our newly developed live cell-imaging
platform to discover novel marine natural products and their cellular phenotypic effects against the most lethal
malaria parasite, Plasmodium falciparum.
Methods: A high content live cell imaging platform was used to screen marine extracts effects on malaria.
Parasites were grown in vitro in the presence of extracts, stained with RNA sensitive dye, and imaged at timed
intervals with the BD Pathway HT automated confocal microscope.
Results: Image analysis validated our new methodology at a larger scale level and revealed potential antimalarial
activity of selected extracts with a minimal cytotoxic effect on host red blood cells. To further validate our assay,
we investigated parasite’s phenotypes when incubated with the purified bioactive natural product bromophycolide
A. We show that bromophycolide A has a strong and specific morphological effect on parasites, similar to the ones
observed from the initial extracts.
Conclusion: Collectively, our results show that high-content live cell-imaging (HCLCI) can be used to screen
chemical libraries and identify parasite specific inhibitors with limited host cytotoxic effects. All together we
provide new leads for the discovery of novel antimalarials.
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Background
Malaria remains a major public health issue in developing
nations. In 2006, the World Health Organization
reported approximately 250 million cases of malaria,
which caused 1 million deaths a year [1]. Despite such a
high number of deaths per year, malaria is a curable dis-
ease and traditional medicinal plants have been used for
treatment since antiquity. Native Peruvians used the bark
of the Cinchona succirubra (Rubiaceae) tree for centuries
before quinine was isolated from it in 1820 [2]. Its semi-
synthetic derived compound, chloroquine (CQ), became
the prophylactic treatment for malaria in 1947 and was
the most effective treatment until CQ-resistant strains
appeared in 1957. In 1972, a new natural product, arte-
misinin, was isolated from Artemisia annua, a plant used
in traditional Chinese medicine for over 2000 years [3].
Artemisinin-based combination therapies (ACTs) are
currently our last resort in combating malaria infection.
Unfortunately, the first ACT-resistant strains appeared in
Cambodia in 2009 and hasten the need for new antima-
larials [4]. In the long history of drug discovery against
the human malaria parasite it is clear that natural pro-
ducts have outlived many synthetic drugs and remain a
valuable resource in identifying efficient and long lasting
novel antimalarials.
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and natural therapeutic agents against the malaria parasite
is based on high-throughput screening (HTS) on the
whole organism. Large collections of small molecule
libraries can be tested directly against parasite growth in
culture [5-8]. Traditionally, the [3
H]hypoxanthine incor-
poration assay was the gold standard to determine, in
vitro, the drug susceptibility of the malaria parasite [9].
This method has now been largely replaced by less hazar-
dous, cost and labor efficient DNA dye intercalation assays
(SYBR Green I [10,11], Pico green [12], 4’, 6-diaminino-2-
phenylindole (DAPI) [13]), assays using quantum dots
labeling late stage infected erythrocytes [14], and assays
using parasites that stably express cytoplasmic firefly luci-
ferase [15,16]. While the various DNA dye assays are cap-
able of quantifying parasite growth, they are limited to
testing a simple survival count and do not efficiently detect
the effect of drug treatment at the morphological level or
provide information of a potential drug’s cytotoxicity. Cur-
rent screenings with parasite strains expressing green
fluorescence protein (GFP) have facilitated the observation
of the dynamic behaviors of parasite phenotype in a real-
time manner. However, these techniques require the use
of a modified cell line for all screening purposes.
Recently, we developed a semi-automated RNA fluores-
cence-based high-content live cell-imaging (HCLCI) assay
that has multiple advantages [17]. It is a fast, simple and a
one-step fluorescence-based assay that can be used with
any type of Plasmodium laboratory and field isolate
strains. It can detect a very low number of live parasites,
their morphological stages and their transcriptional activ-
ities. When high-quality bioimaging microscopes and
image- analysis tools are combined, these screening plat-
forms can facilitate the detection of cytotoxicity or cellular
phenotypic changes in the parasite population and its host
cell. Therefore, this assay can potentially lead to the dis-
covery of novel drugs with novel modes of action and a
hint toward the identification of their cellular targets.
In this study, we have used our new live cell confocal
imaging platform to identify new parasite inhibitors from
crude extracts and their specific morphological effects on
Plasmodium falciparum. Our natural product library was
first extracted from a rich source of various sessile marine
organisms (e.g., red macroalgae, benthic cyanobacteria,
cnidarians, and sponges). Sessile marine organisms are
exposed to numerous pathogens and predators in seawater
and have developed effective natural chemical defenses
[18,19]. Their natural products have been shown to have
biological activity against a wide range of human cancer
cell lines and several infectious agents [20,21].
To screen our marine natural product library for anti-
malarial activity, we first employed a standard SYBR
Green I based assay. Extracts that inhibited parasite
growth at low concentrations were then subjected to a
secondary HCLCI screen to examine parasite morpholo-
gies and the toxicity of natural product treatment on
host red blood cells. Collectively, this live cell-imaging
assay improves the spatial and temporal resolution of the
malaria parasite screening assay, and provides valuable
information about the health of host cells under drug
treatment. Potent novel antimalarials were identified and
they produced phenotypic irregularities in the malaria
parasite, but had minimal cytotoxic effects on host red
blood cells. Further validation of our methodology was
achieved using the newly purified natural compound bro-
mophycolide A. All together our data demonstrate that




3D7, HB3 and Dd2 P. falciparum malaria parasites (MRA-
102, 155, 156, MR4, ATCC
® Manassas, Virginia) were cul-
tured in human type O + erythrocytes in complete med-
ium (RPMI 1640 w/L-Glutamine, w/o Phenol Red (Gibco),
0.043 mg/mL Gentamicin (Gibco), 0.014 mg/mL Hypox-
antine (Acros), 38.5 mM HEPES (Promega), 0.18% Sodium
Bicarbonate (Gibco), 0.2% Glucose (MP Biomedical), 2.6
mM NaOH (Sigma), 0.20% Albumax (Gibco), 5% human
serum) as previously described [22]. Cultures were main-
tained in 25-cm2 flasks (Corning) at a volume of 10 ml
and were gassed for 30 s with an environment of 3% CO2,
1% O2, and 96% N2, then incubated at 37°C. Synchroniza-
tion of culture was achieved through sorbitol lysis of
mature stage using 5% sorbitol (Fisher) fine-tuned by
another lysis 8 h later (27).
Marine organism extracts
Each marine organism was exhaustively extracted with
methanol, and the extracts were combined, filtered, and
reduced in vacuo. The crude extract was separated with
HP20ss resin into four fractions, eluting with (1) 1:1
methanol: water, (2) 4:1 methanol: water, (3) 100% metha-
nol, and (4) 100% acetone.
Plasmodium falciparum SYBR Green I-based fluorescence
growth inhibition assay
Extracts were diluted into three different concentrations,
100, 33, and 11 μg/ml, by the Biomek FXP Laboratory
Automation Workstation (Beckman Coulter, Inc., Brea,
CA) into clear bottom 96-well plates (Costar #3904).
P. falciparum cultures were added at a 2.5% hematocrit
with a 1% parasitemia to 96-well plates and incubated for
72 h at 37°C. Plates were frozen at -80°C overnight. Lysis
buffer (20 mM Tris-HCl, 5 mM EDTA, 0.008% saponin,
0.08% Triton X-100, and 0.2 μl/ml SYBR Green I dye
(Invitrogen #S7585)) was added to thawed plates and
incubated at 37°C. Microtiter plate was read using the
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Data were analyzed with SoftMax Pro v5 (Molecular
Devices Software, Inc., Sunnyvale, CA). The formula z’ =
1 - (3SD+ + 3SD-)/|Ave + - Ave-| was used to calculate
the Z’ value. Where SD + represents the positive control
standard deviation, SD- the negative control standard
deviation, Ave + the mean value of the positive control,
and Ave- the mean value of the negative control.
Bacterial growth inhibition assay
Methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant Enterococcus faecium (VREF) as test
pathogens were used to perform antibacterial assays. As
previously described [20], these bacteria were grown in
GYT media (1 g glucose, 2.5 g yeast extract, 5.0 g tryptone,
1 L H2O) overnight at 37°C. Cultures were diluted to an
optical density of 0.04-0.06, diluted 10-fold, and then
250 μg/ml of extracts were added to microtiter plates.
Extracts were serially diluted for a total of 8 dilutions, and
the plates were incubated for 16-18 h at 37°C. The optical
density was then measured at 600 nm using a Molecular
Devices Emax microplate reader and the minimum inhibi-
tory concentration (MIC) was calculated for each com-
pound using the analysis program SOFTmax PRO.
Fungal growth inhibition assay
As previously described [20] amphotericin B-resistant
Candida albicans was grown overnight at 30°C in RPMI
media (Invitrogen). The indicator Alamar Blue 100 ×
(TREK Diagnostic Systems) was added to the cell sus-
pension at 1 × 104 cells/mL, and then cells were added
to microtiter plates. Extracts were added to 96-well
plates at 250 μg/ml, serially diluted for a total of 8 dilu-
tions, and incubated for 12-15 h at 37°C. The visual
assessment of colorimetric changes was done using a
BioTek model ELx800 microplate reader to detect the
altered oxidation state of Alamar Blue. Plotting the
absorbance versus compound concentration indicated
cell proliferation.
High-content live cell imaging assay, Montage analysis
Samples were prepared in optical bottom 96-well assay
plates (Costar #3614, Corning, NY). Parasite cultures
were diluted to 0.025% hematocrit with a 6% parasite-
mia in complete medium and 240 μl was added to each
well. RNA-probe 132A was incubated with samples for
30 min at 37°C, in the dark at a final concentration of 5
μM. The BD Pathway HT (BD Biosciences Bioimaging,
Rockville, MD) incubation chamber was set at 37°C and
5% CO2. Individual wells were fluoresced by Semrock
(Rochester, NY) Texas Red BrightLine filter sets. A 3 ×
3 tiling composed montage images to examine approxi-
mately 1500 red blood cells.
IC80 phenotypic assay
Parasite cultures were synchronized using 5% sorbitol as
previously described [23]. Cultures were then diluted to
1.67% hematocrit with a 6% parasitemia for ring stage and
3% mature stage in complete medium to reach a final
volume of 240 μl. Treatment with extracts or bromophy-
colide A at their respective IC80 values were added at 0, 8,
and 16 h, and image analysis occurred at 24 h.
Results and Discussion
Crude extract library preparation
To investigate novel antimalarial compounds, we pre-
pared a library of crude extracts derived from various
marine organisms including red, green, and brown
macroalgae, cyanobacteria, cnidarians, and sponges col-
lected from the Fiji Islands. Figure 1, a schematic flow
chart, illustrates the key steps in our screen. Extracts
were first separated by reversed-phased column chroma-
tography and four fractions ranging in compound polar-
ity were collected for each individual organism. All
fractions were tested for antimalarial activity.
Primary bioactivity screen of natural products
Our extract library was screened for antimalarial activity
using a standard high-throughput (HT) SYBR Green I
based assay. We employed the Biomek automated liquid
handling system to aliquot extracts into three different
concentrations (100, 33, and 11 μg/ml) in 96-well plates.
P. falciparum cultures were added and incubated for
72 h before being subjected to a HT assay to evaluate
parasite growth by relative fluorescence intensity of the
nucleic acid dye SYBR Green I. To validate the quality of
our HT SYBR Green I assay we calculated its Z-factor,
which is a high-throughput assay quality assessment. An
ideal Z-factor is 1.0, and below a 0.5 is a marginal assay.
Our primary screen Z-factor value was 0.669, indicating
an excellent primary assay to determine parasite growth
inhibition based on relative fluorescence units. From the
initial library of 2685 marine extracts examined, 27
extracts inhibited parasite growth below 11 μg/ml. With
approximately 1% of extracts found to be potent inhibi-
tors and based on our Z-factor score, our primary assay
is efficient and effective for screening our library and
marine organisms are a novel source for new antimalarial
therapies. While this assay gives us an indication of the
parasite survival, it does not provide any indication of the
drug effects on the parasite morphology and potential
toxicity on host red blood cells (RBCs).
Secondary high-content live cell imaging screen
To further validate antimalarial activity, extracts that
inhibited parasite growth below 11 μg/ml were selected
and subjected to a secondary HCLCI screen. By using
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sites in host red blood cells. For this secondary screen,
we used the Bioscience Pathway HT, an inverted confo-
cal microscope with a motionless stage in a climate-con-
trolled environment together with a fluorescent RNA
selective probe (132A). This RNA probe has previously
been shown to permeate infected erythrocytes without
additional lysis buffers or detergents [17]. When com-
pared to DNA binding dyes (DAPI, Hoechst) used in
current HT antimalarial screens, our selected RNA
probe diffuses throughout the cytoplasm and provides
detailed live cell staining of P. falciparum.U s i n gt h i s
methodology we were able to evaluate the parasitemia,
morphology and transcriptional activity under drug
treatment. In addition to that information, the trans-
mitted light images provide valuable information on
potential toxic effects of the extracts on host RBC mor-
phology. For example, it has been previously observed
that erythrocytes crenate and transform into echinocytes
when cell membranes are perturbed [24]. A characteristic
of an altered RBC membrane is the formation of small
knoblike spicules on the membrane surface that causes
the cell to transform from a biconcave disk, discocyte, into
a sea urchin-like shape, echinocyte. There are 3 stages of
echinocyte transformation. In stage 1 RBCs start to have
an irregular contour disk shape, stage 2 cells are still flat
with spicules, and stage 3 cells have an even distribution
of 10-30 spicules on the surface [25]. Transmitted light
images provide insight whether extracts compromise host
RBC integrity and therefore parasite survival, or if the
extracts specifically target parasites. Cytotoxic effects of
marine extracts on RBC were evaluated by the degree and
amount of echinocyte transformation relative to untreated
cultures. Extracts that caused cultures to have a 50%
increase of stage 3 echinocytes, when compared to
untreated cultures, were considered toxic.
From the secondary screen, 10 of these extracts were
observed to have minimal echinocyte transformation
when compared to untreated parasite culture (data not
shown). This second set of selected extracts most likely
has a specific antimalarial effect with limited toxicity on
RBC integrity.
Determination of antimalarial specificity of our selected
extracts
To further validate our screening procedure, we deter-
mined the IC50 values of our selected extracts using the
classical SYBR Green I Assay. We found that their exact
IC50 ranged from 6.65 ng/ml to 0.85 μg/ml (Figure 2).
Next we compared the antimalarial IC50 values to the IC50
values of these extracts against various infectious agents
(e.g. methicillin-resistant Staphylococcus aureus (MRSA);
vancomycin-resistant Enterococcus faecium (VREF); and
both wild type and amphotericin B-resistant Candida albi-
cans (WTCA and ARCA, respectively). MRSA is a patho-
genic bacterium that causes skin and soft-tissue infections
and is associated with sepsis and necrotizing pneumonia.
VREF is another infectious bacterium that commonly
causes urinary tract infections and can cause neonatal sep-
sis and meningitis. C. albicans is a fungus that lives in the
gut of 80% of the human population, but can be lethal in
immunocompromised patients. Most extracts were inac-
tive against WTCA and ARCA. Results show that our
selected extracts inhibit growth of the P. falciparum 3D7
strain at 10-200-fold lower concentrations compared to
other infectious agents (Table 1). Overall, our data
obtained from the microscopic analysis of parasite and
host RBC and other infectious agents indicated that our
selected extracts are most active against P. falciparum.
Phenotypic analysis of parasites incubated with extracts
To further investigate the potential mode of action of
potent extracts, we examined Plasmodium morphology
within 24 h of treatment. Synchronized parasite cultures
were incubated with IC80 concentrations of extracts at the
early and mature stages of the erythrocytic cycle. As
shown in Figure 3a, untreated parasites displayed a robust
fluorescent signal with an average of 1000 relative fluores-
cence units (RFUs) per frame, indicating a high level of
RNA and consequently an active transcriptional state. In
the transmitted light images, hemozoin, the byproduct of
hemoglobin catabolism, can be observed in all stages as a
dark pigmented region within the parasites. We also
detected a tight and continuous cell cycle progression dur-
ing our first 24 h of observation. In contrast to this
Figure 1 A schematic diagram of natural products antimalarial screen. Marine organisms were collected from the reef off the Fijian Islands.
Extracts were aliquoted into 96-well microtiter plates and cultures were subsequently added. A SYBR Green I based assay was used as a primary
screen of 2685 extracts. Extracts that inhibited P. falciparum growth were subjected to a high-content live cell imaging secondary screen.
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site growth was inhibited at the late ring and early tropho-
zoite stage (Figure 3b). Parasites treated at the mature
stage displayed a decrease of RNA fluorescence signal
intensity to an average of 400 RFUs per frame in ring
stage parasites. Following our phenotypic observations, it
is highly possible that extract G-0490-3 targets a protein
or a pathway essential to the early stage of the parasite
intraerythrocytic cycle. This phenotype has been observed
with Cinchona alkaloid treatment, which arrest develop-
ment of P. falciparum at the mature trophozoite stage [3].
While extract G-0490-3 appeared to be ring stage specific,
the cyanobacteria extract G-0580-3 produced a different
effect on parasite phenotype (Figure 3c). When this extract
was added to ring stage parasites, we observed enlarged
vacuoles adjacent to hemozoin. When the same extract
was added at the mature stage, multiple abnormal
vacuoles appeared (16 h) and parasites were unable to
egress properly (24 h). Giemsa stained blood smears con-
firmed the appearance of large vacuoles. This phenotype
has been previously observed with inhibitors targeting pro-
tease in the parasite food vacuole. Enlarged food vacuoles
are observed due to an accumulation of undegraded globin
[26]. All together these data suggest that G-0580-3 may
target a similar pathway. Similar phenotypes were
observed with treatment with samples G-0005-4 (Figure
3d), G-0049-4 (Figure 3e), and G-0021-3 (not shown) and
all were extracted from the red macroalga Callophycus ser-
ratus. To investigate the morphological effects of our
selected extracts, we further examined their effects on
Figure 2 IC50 graph of potent antimalarial extracts. An inhibitory concentration at 50% growth (IC50) graph of extracts inhibiting parasites at
concentrations 6.65 ng/ml to 0.85 μg/ml.
Table 1 IC50 values of seven extracts in P. falciparum and
other microbes
3D7 MRSA VREF WTCA ARCA
G-0005-4 0.680 ± 0.13 NT 16.4 227 156
G-0021-3 0.790 ± 0.17 11.9 15.2 > 250 250
G-0049-4 0.916 ± 0.19 8.5 7.1 221 225
G-0335-3 0.775 ± 0.25 62.5 > 250 > 250 > 250
G-0355-3 0.131 ± 0.02 1.9 69.2 > 250 > 250
G-0488-3 0.119 ± 0.03 0.5 > 250 1.08 1.11
G-0490-3 0.163 ± 0.02 1.26 67.61 > 250 > 250
G-0494-4 0.137 ± 0.02 0.5 0.5 > 250 > 250
G-0580-3 0.0055 ± 0.01 92.26 153.11 > 250 > 250
G-0588A-3 0.847 ± 0.09 39.9 107.5 150 150
Extracts are considered a ‘hit’ if IC50 < 100 μg/mL, and extracts with > 250 μg/
mL are considered not active. IC50 values for 3D7 P. falciparum strain are
significantly lower than other microbes (MRSA: methicillin-resistant
Staphylococcus aureus; VREF: vancomycin- resistant Enterococcus faecium;
WTCA: wild type Candida albicans; ARCA: amphotericin-B-resistant Candida
albicans). NT indicates not tested, values for P. falciparum 3D7 samples are
from duplicates, and the values for MRSA, VREF, WTCA, or ARCA screens are
from a single experiment. Unit values are in μg/mL.
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parasites were stained with RNA probe 132A. Figure 3a are images of the P. falciparum 3D7 strain without any drug treatment at the ring and
mature stage (control). Figure 3b displays the phenotype of extract G-0490-3, stunted growth of parasites at the trophozoite stage. Figure 3c
displays the phenotype of extract G-0580-3, arrowheads indicate the enlarged food vacuoles at the early stages of the cell cycle. Figure 3d and
Figure 3e, extract G-0005-4 and G-0049-4 respectively, inhibit parasite life cycle progression, decrease hemozoin, and hinder egression.
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sensitive, HB3 (Figure 4b) strains. In Dd2, HB3 and the
reference 3D7 strain, we observed the almost identical
morphological phenotype of stunted hemozoin formation
and cell cycle arrest. Collectively, by using the HCLCI
assay we can observe phenotypic changes that can be used
as a guide to identifying antimalarial properties on drug
resistant and sensitive parasite strains.
Verification of method using initial extracts from purified
bioactive compound bromophycolide A
The purified bioactive compound, (bromophycolides (A-
U)), present in G-0005-4, G- 0049-4, and G-0021-3
extracts isolated from C. serratus [20,27-29] was shown
to inhibit parasite growth at a sub-micromolar range
(IC50 value of 0.7 μM [28]; IC80 value of 2.8 μM). To
understand the morphological effects of pure bromophy-
colide A on P. falciparum 3D7 cultures, we synchronized
parasites and treated cultures at its IC80 value at the early
and late stage of the parasite erythrocytic cycle (Figure
5). Using our high-content live cell-imaging assay, we
detected an immediate arrest of cell cycle progression at
every stage tested, a decrease in RNA intensity and an
enlargement of the food vacuole in the parasite. Further-
more we observed a hindrance of hemozoin formation
from the ring to trophozoite stage. All together, our
Figure 4 Morphological analysis of various strains of P. falciparum. Treatments with extract G-0021-3 on synchronized parasites at the ring
and mature stage. A) chloroquine sensitive strain, HB3; and B) chloroquine resistant strain, Dd2.
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ials and suggest starting hypotheses for understanding
the molecular processes targeted by extracts and their
purified bioactive compounds.
Within the past decade significant advancements in
high-throughput antimalarial drug screening have effi-
ciently reduced time, labor and costs. However, it
remains a challenge to determine the mode of action of
active compounds [30]. We propose in this work to use
our HCLCI assay to screen large libraries for antimalarial
properties. The HCLCI assay is straightforward and
allows for semi-automated image analysis of parasite
drug resistant and sensitive strains without laborious
steps (ex. blood smears, fixation, centrifugation, or
aspiration steps). An additional advantage of our assay is
the ability to observe cytotoxic effects on host red blood
cell. Our method can detect parasite morphological
changes to select for specific phenotypes, and further
select the extracts for the purification of a single bioactive
compound with activity against malaria parasite growth.
We observed a distinct phenotype of cell cycle arrest and
lack of hemozoin formation when cultures were incu-
bated with extracts from which bromophycolide A was
purified and thus pure bromophycolide A as well. These
observations indicated that bromophycolide A’s potential
mode of action may prevent hemozoin formation.
Further investigation using a fluorescent coumarin
tagged bromophycolide A for sub-cellular localization
and molecular target identification studies validated that
heme crystallization was disrupted by the natural product
bromophycolide A [31].
Conclusions
In this study we investigated 2685 extracts from sessile
marine organisms collected in Fijian waters and success-
fully identified nine selective extracts that exhibited para-
site growth inhibition without compromising RBC
membrane integrity. Furthermore we were able to validate
that the purified bioactive compound bromophycolide A
extracted from the red macroalga C. serratus, had similar
morphological effects compared to the initial tested crude
extracts. Collectively, we demonstrate that by using our
newly developed screening we can quickly select a desired
phenotype from crude extracts to act as a guide to the
purification of a single antimalarial compound. Specific
parasite phenotypes can provide insight on how extracts
act on the whole organism, thus presenting a starting
point to test hypotheses regarding the potential drug’s
mode of action. In the antimalarial drug field, targeting
the parasite at different stages of the life cycle by combina-
torial drug treatment is highly recommended to prevent
drug resistance. By implementing our screen to classical
drug discovery methods, we can expedite the discovery of
molecules that can target distinct parasitic stages and lead
to new combination drug therapies.
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